TD Asset Management Inc. lowered its stake in Celgene Co. (NASDAQ:CELG) by 28.0% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 244,673 shares of the biopharmaceutical company’s stock after selling 95,087 shares during the quarter. TD Asset Management Inc.’s holdings in Celgene were worth $22,618,000 as of its most recent filing with the SEC.
Other institutional investors also recently added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund grew its stake in Celgene by 4.6% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 273,716 shares of the biopharmaceutical company’s stock valued at $25,302,000 after acquiring an additional 12,071 shares during the period. Capital Management Corp VA acquired a new stake in Celgene in the 1st quarter valued at $10,955,000. Gilman Hill Asset Management LLC grew its stake in Celgene by 18.6% in the 2nd quarter. Gilman Hill Asset Management LLC now owns 7,416 shares of the biopharmaceutical company’s stock valued at $686,000 after acquiring an additional 1,165 shares during the period. Canyon Capital Advisors LLC acquired a new stake in Celgene in the 1st quarter valued at $119,226,000. Finally, Ruffer LLP acquired a new stake in Celgene in the 1st quarter valued at $226,613,000. 74.19% of the stock is currently owned by hedge funds and other institutional investors.
Shares of CELG opened at $94.74 on Friday. Celgene Co. has a 52-week low of $58.59 and a 52-week high of $98.97. The company has a quick ratio of 3.32, a current ratio of 3.44 and a debt-to-equity ratio of 1.97. The firm’s fifty day moving average is $92.80 and its two-hundred day moving average is $92.51. The stock has a market cap of $67.15 billion, a PE ratio of 12.45, a price-to-earnings-growth ratio of 0.43 and a beta of 1.46.
CELG has been the topic of a number of research analyst reports. ValuEngine cut shares of Celgene from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 1st. BidaskClub raised shares of Celgene from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 3rd. Cowen reaffirmed a “hold” rating and set a $102.00 target price on shares of Celgene in a research note on Tuesday, July 30th. Barclays cut shares of Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 target price on the stock. in a research note on Friday, May 3rd. Finally, Zacks Investment Research raised shares of Celgene from a “sell” rating to a “hold” rating and set a $94.00 target price on the stock in a research note on Tuesday, July 23rd. Two analysts have rated the stock with a sell rating, sixteen have given a hold rating and four have assigned a buy rating to the company’s stock. Celgene currently has an average rating of “Hold” and a consensus target price of $94.81.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Article: Google Finance Portfolio
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.